Objective: Early detection of colon cancer/dysplasia |
|
Patient population: Patients with a known diagnosis of IBD whose disease is in endoscopic remission. Active inflammation precludes a detailed assessment of colonic dysplasia. |
Highlight BoxThe applicability of some suggested recommendations in these guidelines may be impacted by the IBD practitioners’ access to recommended resources (colonic dye spray / virtual chromoendoscopy). |
This care protocol aims to provide IBD providers guidelines for colonic dysplasia/cancer surveillance based on patients’ risk.
Patient Populations |
Recommendation |
Ulcerative colitis extending beyond the rectum or Crohn’s colitis involving 1/3 or more of the colon, has had disease for at least 8 years |
Surveillance colonoscopy recommended, frequency according to risk (see Figure 1) (PACE QPI 11) |
Ulcerative colitis or Crohn’s colitis (of any duration) and has coexisting primary sclerosing cholangitis (PSC) |
Annual surveillance colonoscopy (PACE QPI 10) |
Ulcerative colitis or Crohn’s colitis has confirmed dysplasia in flat mucosa |
Early repeat colonoscopic surveillance using pancolonic dye spray or virtual chromoendoscopy (interval depending on dysplasia risk). Consider surgical referral in very high-risk cases (i.e. high-grade dysplasia or multi-focal dysplasia) (PACE QPI 19) |
Ulcerative colitis or Crohn’s colitis has confirmed visible dysplasia |
Continued endoscopic surveillance if confirmed complete endoscopic resection and no invasive cancer on histology (interval depending on dysplasia risk); otherwise, surgical referral |
Total proctocolectomy with an ileal pouch-anal anastomosis (IPAA) |
Surveillance endoscopy according to risk (see Figure 2) |
IBD with a subtotal colectomy |
Consider surgical referral for a completion proctectomy as an alternative to ongoing endoscopic dysplasia surveillance; otherwise, endoscopic surveillance every 1- 5 years, depending on risk factors for colorectal cancer (See Figure 1). (PACE QPI 8) |
Bisschops R, East JE, Hassan C, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 12 2019;51(12):1155-1179. https://doi.org/10.1055/a-1031-7657
Cairns SR et al. Guidelines for colorectal cancer screening and surveillance in moderate and high-risk groups (update from 2002). Gut 2010;59:666–89. https://doi.org/10.1136/gut.2009.179804
Feakins RM. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. Journal of Clinical Pathology 2013; 66(12):1005-26. https://doi.org/10.1136/jclinpath-2013-201885
Lamb et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68:s1-s106. https://doi.org/10.1136/gutjnl-2019-318484
Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. Jun 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008 https://doi.org/10.1093/ecco-jcc/jjx008
Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology. 09 2021;161(3):1043-1051.e4. https://doi.org/10.1053/j.gastro.2021.05.063